Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 19/20 | 0.75 |
| ▸ | CNR2 | P34972 | 3/20 | 0.59 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.46 |
| ▸ | TACR2 | P21452 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3847085 | 1.00 | CNR1 (0.75) | CNR1CNR2EGLN1TACR2 | |
| SCHEMBL3845796 | 0.89 | CNR1 (0.74) | CNR1CNR2TACR2 | |
| SCHEMBL3845794 | 0.89 | CNR1 (0.74) | CNR1CNR2TACR2 | |
| SCHEMBL3867358 | 0.89 | CNR1 (0.74) | CNR1CNR2TACR2 | |
| SCHEMBL3867354 | 0.89 | CNR1 (0.74) | CNR1CNR2TACR2 | |
| SCHEMBL1379163 | 0.87 | CNR1 (0.75) | CNR1CNR2TACR2 | |
| SCHEMBL3845133 | 0.87 | CNR1 (0.75) | CNR1CNR2TACR2 | |
| SCHEMBL2702493 | 0.85 | CNR1 (1.00) | CNR1CNR2TACR2 | |
| SCHEMBL2702496 | 0.85 | CNR1 (1.00) | CNR1CNR2TACR2 | |
| SCHEMBL2702498 | 0.85 | CNR1 (1.00) | CNR1CNR2TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1868999-B1 | PYRIDINE-3-CARBOXAMIDE DERIVATIVES AS CB1 INVERSE AGONISTS | HOFFMANN LA ROCHE (CH) | 2009-07-01 | — | — | EP | claimed |
| US-7229999-B2 | Pyridine-3-carboxamide derivatives as CB1 inverse agonists | HOFFMANN-LA ROCHE INC. (US) | 2007-06-12 | — | — | US | claimed |
| US-20060229326-A1 | Pyridine-3-carboxamide derivatives as CB1 inverse agonists | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-12 | — | — | US | claimed |
| EP-1868999-B1 | PYRIDINE-3-CARBOXAMIDE DERIVATIVES AS CB1 INVERSE AGONISTS | HOFFMANN LA ROCHE (CH) | 2009-07-01 | — | — | EP | disclosed |
| US-7229999-B2 | Pyridine-3-carboxamide derivatives as CB1 inverse agonists | HOFFMANN-LA ROCHE INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-20060229326-A1 | Pyridine-3-carboxamide derivatives as CB1 inverse agonists | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229326-A1 | Pyridine-3-carboxamide derivatives as CB1 inverse agonists | CNR1, CNR2, GPR119 | CNR1 1/4885CNR2 2/4885EGLN1 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.